Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ET140203 T Cells

PreclinicalSmall molecule

EEureka Therapeutics Inc.

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatoblastomaRecruiting

HepatoblastomaPreclinical

Recruiting

Timeline

Expected Milestones

Q1 2028

PreclinicalRecruiting

Hepatoblastoma

NCT04634357

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)

Terminated·EEureka Therapeutics Inc.·Phase 1·NCT04502082·8 enrolled

Hepatoblastoma1 trial

An Open-Label, Dose Escalation, Phase I/II Clinical Trial of ET140203 T Cells in Pediatric Subjects With Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)

Recruiting·EEureka Therapeutics Inc.·Preclinical·NCT04634357·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ET140203 T Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ET140203 T Cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ET140203 T Cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eureka Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: EEureka Therapeutics Inc.

Related News